senti biosciences is a team of engineers, scientists, and entrepreneurs on a mission to leverage synthetic biology to treat the most pressing diseases. they have pioneered new technology platforms to design synthetic gene circuits for adaptive cell and gene therapies. their recently completed series a round of funding will be used to further the growth of their scalable therapeutic design platform and advance therapeutic candidates towards the clinic. they are proud to count nea, 8vc, amgen ventures, pear ventures, lux capital, menlo ventures, allen & company, nest.bio, omega funds, goodman capital, and lifeforce capital among their investors.
Company profile
Ticker
SNTI
Exchange
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
Former names
Dynamics Special Purpose Corp., Senti Biosciences, Inc.\
SEC CIK
Corporate docs
IRS number
862437900
SNTI stock data
Latest filings (excl ownership)
10-K
2023 FY
Annual report
21 Mar 24
8-K
Senti Bio Reports Fourth Quarter and Full Year 2023 Financial Results and Reviews Recent Highlights
21 Mar 24
8-K
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
6 Feb 24
S-8
Registration of securities for employees
10 Jan 24
8-K
Senti Bio Announces Strategic Steps to Prioritize Investment in Lead Clinical Program
5 Jan 24
8-K
Regulation FD Disclosure
22 Dec 23
10-Q
2023 Q3
Quarterly report
13 Nov 23
8-K
Senti Bio Announces Third Quarter 2023 Results and Pipeline Updates
13 Nov 23
424B3
Prospectus supplement
13 Nov 23
424B3
Prospectus supplement
13 Nov 23
Latest ownership filings
4
Kanya Rajangam
2 Feb 24
4
Timothy K Lu
2 Feb 24
4
DEBORAH KNOBELMAN
2 Feb 24
4
Edward T Mathers
21 Jun 23
4
Susan D Berland
21 Jun 23
4
James J. Collins
21 Jun 23
4
BRENDA COOPERSTONE
21 Jun 23
4
Omid Farokhzad
21 Jun 23
SC 13G
PRICE T ROWE ASSOCIATES INC /MD/
14 Feb 23
SC 13G/A
Sculptor Capital LP
14 Feb 23
Financial summary
Quarter (USD) | Sep 23 | Jun 23 | Mar 23 | Dec 22 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 22 | Dec 21 | |
---|---|---|---|
Revenue | |||
Cost of revenue | |||
Operating income | |||
Operating margin | |||
Net income | |||
Net profit margin | |||
Cash on hand | |||
Change in cash | |||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 45.83 mm | 45.83 mm | 45.83 mm | 45.83 mm | 45.83 mm | 45.83 mm |
Cash burn (monthly) | (no burn) | 6.03 mm | 14.63 mm | 9.06 mm | 5.13 mm | 4.53 mm |
Cash used (since last report) | n/a | 41.12 mm | 99.68 mm | 61.73 mm | 34.94 mm | 30.88 mm |
Cash remaining | n/a | 4.70 mm | -53.85 mm | -15.90 mm | 10.89 mm | 14.95 mm |
Runway (months of cash) | n/a | 0.8 | -3.7 | -1.8 | 2.1 | 3.3 |
Institutional ownership, Q2 2023
54.7% owned by funds/institutions
13F holders | Current |
---|---|
Total holders | 31 |
Opened positions | 6 |
Closed positions | 2 |
Increased positions | 6 |
Reduced positions | 4 |
13F shares | Current |
---|---|
Total value | 5.46 bn |
Total shares | 25.04 mm |
Total puts | 0.00 |
Total calls | 0.00 |
Total put/call ratio | – |
Largest owners | Shares | Value |
---|---|---|
Bayer Healthcare | 5.88 mm | $0.00 |
NEA Management | 4.43 mm | $2.78 bn |
New Enterprise Associates 15 | 4.43 mm | $0.00 |
T. Rowe Price | 3.39 mm | $2.12 mm |
Joe Lonsdale | 2.54 mm | $0.00 |
ARK Investment Management | 1.83 mm | $1.15 bn |
INTC Intel | 595.67 k | $373.48 mm |
Vanguard | 553.15 k | $346.83 mm |
Hongkou Capital | 300.53 k | $188.43 mm |
Geode Capital Management | 200.19 k | $124.84 mm |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
1 Feb 24 | Kanya Rajangam | Common Stock | Grant | Acquire A | No | No | 0 | 101,000 | 0.00 | 101,000 |
1 Feb 24 | Kanya Rajangam | Stock Option Common Stock | Grant | Acquire A | No | No | 0.46 | 152,000 | 69.92 k | 152,000 |
1 Feb 24 | Timothy K Lu | Common Stock | Grant | Acquire A | No | No | 0 | 306,000 | 0.00 | 865,496 |
1 Feb 24 | Timothy K Lu | Stock Option Common Stock | Grant | Acquire A | No | No | 0.46 | 459,000 | 211.14 k | 459,000 |
1 Feb 24 | Deborah Knobelman | Common Stock | Grant | Acquire A | No | No | 0 | 101,000 | 0.00 | 131,000 |
1 Feb 24 | Deborah Knobelman | Stock Option Common Stock | Grant | Acquire A | No | No | 0.46 | 152,000 | 69.92 k | 152,000 |
16 Jun 23 | Omid Farokhzad | Stock Option Common Stock | Grant | Acquire A | No | No | 0.99 | 62,500 | 61.88 k | 62,500 |
16 Jun 23 | Brenda Cooperstone | Stock Option Common Stock | Grant | Acquire A | No | No | 0.99 | 62,500 | 61.88 k | 62,500 |